CStone Announces That OmniAb-Derived CS1001 Phase 3 Trial Met Primary Endpoint As First-Line Treatment In Stage IV Squamous, Non-Squamous Non-Small Cell Lung Cancer, Announces Plan To Submit New Drug Application